• Cofoe Medical posted revenue of RMB 2.07 billion, up 38.5% year on year.
• Profit attributable to owners of the parent rose to RMB 202.26 million, up 20.8%; basic earnings per share increased to RMB 0.95, up 15.9%.
• Gross profit climbed to RMB 1.13 billion, up 51.3%, lifting gross margin by 4.6 percentage points to 54.6%.
• Overseas revenue grew to RMB 210 million, more than doubled; net proceeds from the Hong Kong listing totaled about HK$1.01 billion.
• Cofoe proposed an interim dividend of RMB 6 per 10 shares, implying an estimated payout of about RMB 136.28 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cofoe Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304349), on August 28, 2026, and is solely responsible for the information contained therein.